📰 Spherix Network News
Page 4 - Spherix Network News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Spherix Network. Real-time updates on events, politics, business and more.
March 15, 2023
/PRNewswire/ -- With the U.S. commercial launch of TG Therapeutics Briumvi (ublituximab-xiiy) on January 26th, 2023 for the treatment of relapsing multiple...
February 28, 2023
/PRNewswire/ -- Apellis Pharmaceuticals recently made history with the approval of Syfovre (pegcetacoplan) for the treatment for Geographic Atrophy (GA). GA is...
February 28, 2023
/PRNewswire/ -- On February 16, The Lancet Neurology published the Phase 3 results of Pfizers zavegepant for the acute treatment of migraine. The CGRP...
February 24, 2023
/PRNewswire/ -- Argenxs launch of Vyvgart (efgartigimod) has been a success, with global first-year revenue of ~$400 million USD. As the second biologic...
February 17, 2023
/PRNewswire/ -- According to Biogens earnings call on Wednesday, February 15, 2023, sales for its multiple sclerosis (MS) franchise are down for the third...
February 13, 2023
/PRNewswire/ -- The patient switch territory is evolving as more agents become available. Spherixs RealWorld Dynamix™ report allows for an inside look into...
February 9, 2023
/PRNewswire/ -- Since 2017, Spherix Global Insights has been monitoring the U.S. renal anemia market landscape, capturing nephrologists perceptions and...
February 9, 2023
/PRNewswire/ -- Analysis from Spherix Global Insights quarterly market tracker, RealTime Dynamix™: Ulcerative Colitis, reveals that at twenty (20) months after...
February 6, 2023
/PRNewswire/ -- AbbVies Humira (adalimumab) is the worlds best selling drug, but the entry of biosimilar challengers, with Amgens Amjevita being the first...
January 20, 2023
/PRNewswire/ -- With SGLT2 inhibitors increasingly becoming the standard of care for diabetic and non-diabetic CKD patients, the broader CKD treatment has...